LI
The startup develops pharmaceutical products that target medical complications arising from hypoxia, specifically addressing the threats posed by pathogens during epidemics and pandemics. Its solutions enable healthcare providers to effectively treat diseases linked to biothreats, particularly in emerging economies.
Updated 3 months ago
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops pharmaceutical products that target medical complications arising from hypoxia, specifically addressing the threats posed by pathogens during epidemics and pandemics. Its solutions enable healthcare providers to effectively treat diseases linked to biothreats, particularly in emerging economies.